Drugs / [18F]F-PSMA-N5
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06462508 | Apr 2024 → Jun 2025 | prostate cancer | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06462495 | Apr 2024 → Jun 2025 | prostate cancer | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-PSMA-N5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462508 ↗ |
| Modality | Diagnostic / imaging agent | “novel PET imaging agent \[18F\]F-PSMA-N5” NCT06462495 ↗ |
| Route | Intravenous | “single intravenous injection of \[18F\]F-PSMA-N5” NCT06462495 ↗ |